Navigation Links
TB, HIV and malaria vaccine research gets major boost
Date:5/7/2013

Rockville, MD, US, Oxford, UK and Basel, Switzerland 7 May 2013 Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company specializing in T-cell vaccines, today announced a $2.9 million grant to Aeras in support of a collaboration among the three parties to support the development of vaccines against tuberculosis, HIV and malaria.

The grant, provided by the Bill & Melinda Gates Foundation, allows the three groups to work together to develop scalable methods to enable large-scale production of multiple novel chimpanzee adenovirus vector constructs.

"We are pleased to expand our partnership with Okairos focusing on novel constructs utilizing chimpanzee adenovirus for next generation TB vaccines, as well as our collaboration with the University of Oxford, both of which are central to our organizational mission," said Tom Evans, MD, Interim CEO of Aeras. "This effort to improve optimization and scale up under current good manufacturing practices could also potentially benefit our peers in HIV and malaria vaccine development."

Novel constructs to be pursued include Okairos' proprietary technology platform that uses potent chimpanzee adenovirus vectors to stimulate robust T-cell and antibody responses against selected antigens.

Dr Riccardo Cortese, Chief Executive Officer of Okairos, said: "This new collaboration will enable us to advance our promising technology platform. By continuing to work with Aeras and Oxford, partners with proven expertise in vaccines development, we ultimately aim to deliver novel vaccines to developing countries where there is great need."

Aeras and Oxford both bring to the collaboration considerable expertise in vaccine development and manufacturing, with Oxford currently developing multiple vaccines, including vaccines against HIV, malaria and TB in clinical trials in the UK and Africa, and Aeras focusing primarily on tuberculosis vaccine research and development.

"Chimpanzee adenovirus-based vaccines have recently been shown to safely induce exceptionally potent cellular immunity in adults, children and infants, and are in clinical trials involving over 1,000 vaccinees in seven countries," commented Adrian Hill, Director of the Jenner Institute at Oxford University. "The diseases targeted, including malaria, HIV/AIDS and tuberculosis, are the greatest infectious killers of our time so this investment in manufacturing technology is very timely."


'/>"/>

Contact: Annmarie Leadman
aleadman@aeras.org
240-599-3018
Aeras
Source:Eurekalert

Related medicine news :

1. Detecting malaria early to save lives: New optical technique promises rapid and accurate diagnosis
2. New process would make anti-malarial drug less costly
3. UCI researchers create mosquitoes incapable of transmitting malaria
4. The math of malaria
5. Novel anti-malarial drug target identified
6. New research reveals extent of poor-quality antimalarial medicines in South American countries
7. BioMed Central presents Challenges in Malaria Research: Progress Towards Elimination
8. Novel technique demonstrates interactions between malaria parasite and HIV
9. Meddling with male malaria mosquito mating plug to control an epidemic
10. Protein impedes microcirculation of malaria-infected red blood cells
11. New opportunity for rapid treatment of malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... ... why retirement is not an option to senior, upper-level executives speaking at a ... , "A senior, high-level executive is an asset to be fully realized ...
(Date:9/25/2017)... ... September 25, 2017 , ... Leonard Bley, MD ... generation for LASIK in Manhattan with Contoura Vision, the latest WaveLight® topographic-guided laser ... available in the United States to correct nearsightedness and nearsightedness with astigmatism. This ...
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... Earlypicker is ... for a one-stop shop for the hottest Korean cosmetics and fashion trends sweeping the ... a company that’s already well-known for the great offerings that allow Koreans everywhere to ...
(Date:9/25/2017)... ... 2017 , ... Dr. Edward Hebert is celebrating his 33rd anniversary ... else,” said Dr. Hebert. “I count my blessings daily for the opportunity that the ... is what I look forward to the most. The relationships I have with my ...
(Date:9/25/2017)... ... ... “Renew Refresh Restore Reward”: is a story of struggle and how trouble often ... Deborah Freeman, cofounded the Free Spirit Bible Church and currently serves as the church’s ... invited us to come over before the baby had to go back to her ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
Breaking Medicine Technology: